

Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests

Name of Advisory Committee Temporary Voting Member: Marvin Konstam, M.D.

Committee: Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC)

Meeting Date: June 28, 2016

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: The committee will discuss supplemental new drug application (sNDA) 204629 for empagliflozin (Jardiance) tablets and sNDA 206111 for empagliflozin and metformin hydrochloride (Synjardy) tablets. Both sNDAs are sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., for the proposed additional indication in adult patients with type 2 diabetes mellitus and high cardiovascular risk to reduce the risk of all-cause mortality by reducing the incidence of cardiovascular death and to reduce the risk of cardiovascular death or hospitalization for heart failure.

I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
n/a	n/a	n/a
II. Other Imputed Interests		
Contracts/grants	(b) (4) (Competing Firm)	\$0 – 50,000 per year

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/
Signature

June 13, 2016
Date